27th Feb 2024 A plain language summary: BI 1015550 for idiopathic pulmonary fibrosis and progressive pulmonary fibrosis
27th Feb 2024 A plain language summary of the SPRINT study: selumetinib for children with neurofibromatosis type 1 and plexiform neurofibromas
27th Feb 2024 A plain language summary looking at spesolimab treatment for the prevention of flares in people with generalized pustular psoriasis (GPP)
27th Feb 2024 A plain language summary looking at nivolumab that is given after stage 2B/2C melanoma is removed by surgery
23rd Feb 2024 A plain language summary looking at the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small cell lung cancer
14th Feb 2024 Long-term benefits of enzyme replacement therapy in children and teenagers with Gaucher disease type 3- a plain language summary
25th Jan 2024 GATHER1 and GATHER2 studies: a plain language summary looking at whether avacincaptad pegol works and is safe in people with geographic atrophy
25th Jan 2024 The TROPiCS-02 study: a plain language summary on the effectiveness of sacituzumab govitecan in treating HR-positive/HER2-negative breast cancer
25th Jan 2024 The PRIMA study: a plain language summary on the efficacy and safety of individualized niraparib dosing based on body weight and platelet count
25th Jan 2024 Improved symptoms of narcolepsy with cataplexy in adults who used low-sodium oxybate- a plain language summary
22nd Jan 2024 Zanubrutinib or ibrutinib in chronic lymphocytic leukemia that is resistant to treatment or has come back after treatment- a plain language summary
22nd Jan 2024 The VANGUARD study: a plain language summary looking at garadacimab for the prevention of hereditary angioedema attacks:
22nd Jan 2024 The TITAN study: a plain language summary looking at how PSA decline with apalutamide therapy is associated with longer survival and improved outcomes in people with metastatic prostate cancer
22nd Jan 2024 The LAVENDER study: a plain language summary looking at trofinetide treatment for Rett syndrome
22nd Jan 2024 Biosimilars and how they can be used to treat people with cancer- a plain language review
22nd Jan 2024 Two different concentrations of GP2017 (a biosimilar medicine) are associated with similar drug levels in the body- a plain language summary
22nd Jan 2024 A plain language summary looking at isavuconazole to treat mold infections in Asia and the Western Pacific region
22nd Jan 2024 A plain language summary of epicutaneous immunotherapy with Viaskin™ Peanut in toddlers
22nd Jan 2024 A plain language summary looking at the long-term benefit of sotorasib in patients with KRAS G12C–mutated non–small-cell lung cancer
22nd Jan 2024 The DESTINY-Breast03 study: a plain language summary comparing trastuzumab deruxtecan with trastuzumab emtansine for breast cancer
22nd Jan 2024 Plain Language Summary: the efficacy and safety of bepirovirsen in people with chronic hepatitis B infection
22nd Jan 2024 A plain language summary of the challenges and solutions for people with antibodies against AAV-based gene therapy
22nd Jan 2024 A plain language summary of the RACE study looking at adding eltrombopag to standard treatment of severe aplastic anemia
22nd Jan 2024 The effect of empagliflozin in patients with heart failure with preserved ejection fraction, with and without diabetes: a plain language summary
18th Jan 2024 Plain language summary: looking at the enfortumab vedotin plus pembrolizumab treatment combination for untreated locally advanced or metastatic urothelial cancer
18th Jan 2024 Insomnia-related fatigue: a plain language summary looking at the effects of lemborexant
17th Jan 2024 Looking at whether genetic testing can help doctors diagnose the severity of MPS I- a plain language summary
20th Nov 2023 A plain language summary comparing pegcetacoplan with supportive care for 26 weeks in participants with paroxysmal nocturnal hemoglobinuria
16th Nov 2023 A plain language summary on the impact of itch on the quality of life in people with primary biliary cholangitis
16th Nov 2023 Plain language summary of the EMPEROR-Preserved : drug treatment with empagliflozin was beneficial in people with heart failure with preserved ejection fraction
15th Nov 2023 A plain language summary of the EMPEROR-Reduced study: drug treatment with empagliflozin lowered risk for hospitalization in people with heart failure with reduced ejection fraction
15th Nov 2023 Plain language summary: A. fumigatus fungi samples that show resistance to antifungal medicines have changes in their genes
14th Nov 2023 A plain language summary of the ARROW study: pralsetinib in patients with RET fusion–positive non-small cell lung cancer
14th Nov 2023 Plain Language Summary of Publication article: the GENEr8-1 study of valoctocogene roxaparvovec gene therapy for hemophilia A
3rd Nov 2023 A plain language summary of erdafitinib in locally advanced or metastatic urothelial carcinoma: a phase 2 study with a long term follow-up
2nd Nov 2023 A plain language summary of the PALOMA-2 and PALOMA-3 studies: the effects of adding palbociclib to endocrine therapy to treat advanced breast cancer
2nd Nov 2023 A plain language summary of the intergenerational promotion of health behaviours in Portuguese families affected by familial amyloid polyneuropathy
6th Oct 2023 A plain language summary of the monarcHER study: abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with HR+, HER2+ advanced breast cancer
6th Oct 2023 The TOPAZ-1 study: a plain language summary describing durvalumab and chemotherapy for advanced biliary tract cancer
22nd Sep 2023 A plain language summary of the HIMALAYA study which looked at tremelimumab and durvalumab for unresectable hepatocellular carcinoma
22nd Sep 2023 A plain language summary looking at marstacimab treatment for people with severe hemophilia A or B
13th Sep 2023 The effect of vibegron on the blood pressure and heart rate in people with overactive bladder: a plain language summary
12th Sep 2023 A plain language summary describing the effect of rapidly rising prostate-specific antigen (PSA) levels on how long men with a type of advanced prostate cancer live and their healthcare costs
11th Sep 2023 A plain language summary of the INTRIGUE study comparing ripretinib with sunitinib in people with advanced gastrointestinal stromal tumour after treatment with imatinib
10th Aug 2023 A plain language summary looking at whether declines in prostate-specific antigen level indicates how long patients with advanced prostate cancer will live when treated with enzalutamide